Roumell Asset Management, LLC Paratek Pharmaceuticals, Inc. Transaction History

Roumell Asset Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 14, 2020	SELL	$2.67 - $4.97 $908,662 - $1.69 Million	-340,323 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$2.93 - $4.5 $1.21 Million - $1.86 Million	-413,559 Reduced 54.86%	340,323 $1.37 Million
Q3 2019 Nov 13, 2019	BUY	$3.08 - $5.76 $231,267 - $432,501	75,087 Added 11.06%	753,882 $3.26 Million
Q2 2019 Aug 13, 2019	BUY	$3.47 - $6.32 $73,213 - $133,345	21,099 Added 3.21%	678,795 $2.71 Million
Q1 2019 May 14, 2019	BUY	$5.36 - $7.24 $1.11 Million - $1.5 Million	207,290 Added 46.02%	657,696 $3.53 Million
Q4 2018 Feb 14, 2019	BUY	$4.8 - $11.6 $953,472 - $2.3 Million	198,640 Added 78.9%	450,406 $2.31 Million
Q3 2018 Nov 13, 2018	SELL	$9.05 - $10.95 $52,164 - $63,115	-5,764 Reduced 2.24%	251,766 $2.44 Million
Q2 2018 Aug 13, 2018	BUY	$10.2 - $13.9 $613,866 - $836,543	60,183 Added 30.5%	257,530 $2.63 Million
Q1 2018 May 14, 2018	BUY	$12.65 - $18.85 $1.22 Million - $1.82 Million	96,668 Added 96.02%	197,347 $2.57 Million
Q4 2017 Feb 13, 2018	SELL	$17.45 - $25.6 $12,564 - $18,432	-720 Reduced 0.71%	100,679 $1.8 Million
Q3 2017 Nov 13, 2017	BUY	$18.9 - $28.2 $1.92 Million - $2.86 Million	101,399	101,399 $2.55 Million

1.54M

Ticker PRTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,862,500
Description
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...

Get notified when there are updates to the investment portfolio of Roumell Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Roumell Asset Management, LLC with notifications on news.